First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis.
<h4>Background</h4>It remains unknown which is the optimal first-line treatment regimen for patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). We performed a network meta-analysis to address this important issue.<h4>Methods<...
Saved in:
| Main Authors: | Hongwei Zhang, Jun Chen, Tingting Liu, Jun Dang, Guang Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0223530&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of first-line afatinib in older patients with advanced EGFR-mutated non-small cell lung cancer
by: Mi-Hyun Kim, et al.
Published: (2025-07-01) -
What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review
by: Chuang Yang, et al.
Published: (2025-08-01) -
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-02-01) -
Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs
by: Jietao Ma, et al.
Published: (2024-10-01) -
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
by: Wenhua Liang, et al.
Published: (2014-01-01)